ナルコレプシー1型患者を対象としたTAK-861の研究

基本情報

NCT ID

NCT05687903

ステータス

完了

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

112

治験依頼者名

Takeda

概要

The main aim of this study is to see how TAK-861 works on symptoms of narcolepsy, including excessive daytime sleepiness and cataplexy. Approximately 100 participants will take part in the study across North America, Europe and Asia Pacific. The treatment (TAK-861 or placebo) will be administered for 8 or 12 weeks. After this treatment period the participant will have the option to participate in a separate, long- term extension study during which all participants will be treated with TAK-861.

対象疾患

介入

依頼者（Sponsor）

実施施設 (9)